Anemia, Aplastic Clinical Trial
Official title:
Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor
A single arm dose optimization study in which all patients are given a fixed dose of Cytoxan (4 x 50 mg/kg) plus ATG (3 x 30 mg/kg) and the TBI dose starting at 3 x 200 cGy is escalated or de-escalated dependent upon engraftment and toxicity.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00997386 -
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
|
Phase 2 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
Completed |
NCT00229619 -
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
|
Phase 2 | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT00005682 -
Aplastic Anemia Epidemiology: Incidence and Case-control
|
N/A | |
Completed |
NCT00692926 -
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
|
Phase 1 | |
Completed |
NCT00244010 -
Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias
|
N/A | |
Recruiting |
NCT00399971 -
Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
|
Phase 1/Phase 2 | |
Completed |
NCT00683046 -
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT00922883 -
A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
|
Phase 2 | |
Recruiting |
NCT00319878 -
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
|
Phase 1/Phase 2 | |
Completed |
NCT00061763 -
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
|
Phase 2 | |
Completed |
NCT00000597 -
Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders
|
Phase 3 | |
Recruiting |
NCT02773225 -
Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)
|
Phase 2/Phase 3 | |
Terminated |
NCT03733249 -
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00737685 -
Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
|
Phase 2 | |
Completed |
NCT00326417 -
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
|
Phase 1/Phase 2 | |
Completed |
NCT00618969 -
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
|
Phase 2 | |
Completed |
NCT00578266 -
Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
|
Phase 1 |